United Asset Strategies Inc. Sells 1,385 Shares of Amgen Inc. $AMGN

United Asset Strategies Inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,269 shares of the medical research company’s stock after selling 1,385 shares during the quarter. United Asset Strategies Inc.’s holdings in Amgen were worth $13,180,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in AMGN. Choreo LLC grew its stake in Amgen by 1.5% in the 3rd quarter. Choreo LLC now owns 18,598 shares of the medical research company’s stock worth $7,839,000 after acquiring an additional 278 shares during the period. Interchange Capital Partners LLC grew its position in shares of Amgen by 1.3% in the third quarter. Interchange Capital Partners LLC now owns 2,139 shares of the medical research company’s stock valued at $902,000 after purchasing an additional 28 shares during the period. Livelsberger Financial Advisory acquired a new position in Amgen in the third quarter valued at $74,000. China Universal Asset Management Co. Ltd. increased its stake in Amgen by 0.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 72,485 shares of the medical research company’s stock valued at $30,708,000 after purchasing an additional 282 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co acquired a new position in Amgen in the third quarter valued at $38,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst support: RBC Capital reaffirmed its Buy rating, while Goldman Sachs and TD Cowen also maintained Buy recommendations. The continued bullish view provides support ahead of earnings. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Rare-disease pipeline progress: Amgen reported Phase 3 data for dazodalibep in Sjögren’s disease, additional long-term UPLIZNA data in IgG4-related disease and other autoimmune conditions, and a diagnostic collaboration aimed at earlier rare-disease detection. The updates reinforce the company’s effort to expand growth beyond its established products. Rare Disease Updates
• Positive Sentiment: Dividend income: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, payable December 11 to shareholders of record November 20. The dividend supports the stock’s income appeal. Amgen Fourth-Quarter Dividend
• Neutral Sentiment: Earnings catalyst: Amgen will report third-quarter 2026 results after the market close on November 3, followed by a conference call. Analysts are focused on whether strong sales of products such as Repatha and TEZSPIRE can offset rising expenses, pricing pressure and biosimilar competition. Amgen Third-Quarter Results Announcement
• Negative Sentiment: Profitability concerns: Management has warned that spending will increase, while MariTide trials could consume substantial cash. Investors are assessing whether higher research and development costs and a CFO transition could pressure margins. Amgen Expense and Profit Outlook

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $460.73 on Friday. The business has a 50-day moving average of $419.32 and a two-hundred day moving average of $374.09. The firm has a market capitalization of $249.08 billion, a PE ratio of 28.63, a P/E/G ratio of 3.31 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $468.27.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the company posted $6.02 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts forecast that Amgen Inc. will post 22.96 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. UBS Group raised their price target on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. Guggenheim lowered their price target on Amgen from $388.00 to $378.00 and set a “neutral” rating for the company in a report on Tuesday, October 13th. Barclays upped their price objective on shares of Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 21st. Bank of America increased their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Finally, Robert W. Baird raised their target price on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $389.71.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.